Passage Bio Raises $216 Million to Fund Gene Therapies for Rare CNS Disorders - Global Genes
Xconomy: Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic
Despite Market Drama, Passage Bio Launches $216 Million IPO – PharmaLive
Gene Therapy Developer Passage Bio Files for $125M IPO
IPO Roundup: Passage Bio Inc, Zhongchao Inc
Passage Bio | Fierce Biotech
Biotech IPOs 2020 and M&A Trends
Passage Bio Announces Pricing of Initial Public Offering
Passage Bio went public during the stock market's worst week since 2008
Covid-19 stalls biotech flotations | Evaluate
IPO Roundup: Passage Bio Inc
Brad's Blog - Biotech IPOs Class of 2020
Passage Bio - Org Chart, Teams, Culture & Jobs | The Org
Passage Bio - 2/27/2020 | Cowen
Simona King, CPA, MBA - Chief Financial Officer - Passage Bio | LinkedIn
Gene therapy heats Passage Bio IPO; new Hatch Fund; rivals join BrokerTech; FS spins AIX; PCI buys, may sell
Philadelphia-based Passage Bio trims workforce by 23% - Philadelphia Business Journal
Passage Bio
Final tally for Philadelphia-based Passage Bio's IPO: $248.4M - Philadelphia Business Journal
Philadelphia gene therapy developer Passage Bio set to go public this week - Philadelphia Business Journal
Philadelphia gene therapy company Passage Bio files plans for $125M IPO - Philadelphia Business Journal
